|
New medicines
GREY AVATROMBOPAG tablets (Doptelet®▼) for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of AVATROMBOPAG tablets (Doptelet®▼) for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures.
GREY ESKETAMINE nasal spray solution (Spravato®▼) for treatment-resistant depression
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ESKETAMINE nasal spray solution (Spravato®▼) for treatment-resistant depression.
GREY UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate to severe rheumatoid arthritis
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate to severe rheumatoid arthritis.
AMBER RETAINED DAPAGLIFLOZIN tablets (Forxiga®) WITH INSULIN for the treatment of type 1 diabetes
The Pan Mersey Area Prescribing Committee recommends the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) WITH INSULIN, for the treatment of type 1 diabetes mellitus in accordance with NICE TA597.
AMBER RETAINED Pathway for addition of SGLT2 inhibitors to insulin therapy for patients with type 1 diabetes
Pathway to support appropriate initiation of SGLT-2 inhibitors in type 1 diabetes by specialist service, including recommendations for safe transfer of prescribing to primary care. To be used in conjunction with dapagliflozin amber retained statement.
AMBER INITIATED INSULIN DEGLUDEC 100units/mL and 200 units/mL solution for subcutaneous injection (Tresiba®) for type 1 and type 2 diabetes
The Pan Mersey Area Prescribing Committee recommends the prescribing of INSULIN DEGLUDEC 100units/mL and 200 units/mL solution for subcutaneous injection (Tresiba®), initiated by specialists only, for type 1 and type 2 diabetes for specific patient groups, taking into account NICE guidance
Formulary and guidelines
RED Inflammatory Bowel Disease High Cost Drug Treatment Pathway for Adults
New guideline to provide clarity on the use of high cost drugs in patients with ulcerative colitis and Crohn’s disease after conventional therapy has failed. Likely to be cost neutral as it should reflect current practice.
Cannabis based medicinal products
Implementation of NICE NG144: Cannabis based medicinal products.
-
AMBER RETAINED for spasticity in multiple sclerosis.
Cannabis extract oromucosal spray (Sativex®) formulary section 10.2.2, designation changed from black to amber retained. Prescribing support document supports process of initiation and ongoing care by specialist, and prescribing in primary care. Estimated annual cost £15,900 - £27,000 per 100,000 population.
AMBER INITIATED Mesalazine m/r (Octasa®) 1,600mg in ulcerative colitis
Higher strength tablet added to existing 400mg and 800mg range. Reduced tablet burden, mariginally more expensive than lower strength tablets (25.7p/400mg compared to 18.4p – 22.4p/400mg).
GREEN Theophylline m/r (Slo-phyllin® brand) in COPD
Brand discontinued. Removed from formulary.
New formulary Chapter 16: Guidance
For noting. Added to accommodate general prescribing advice not easily linked to a therapeutic group of drugs.
Safety
EMOLLIENTS: fire risk
This update is a response to MHRA broadening the scope of their advice on the fire risk regardless of paraffin content.
|
